Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03997643 |
|
Recruitment Status :
Recruiting
First Posted : June 25, 2019
Last Update Posted : January 25, 2023
|
Sponsor:
Lawson Health Research Institute
Information provided by (Responsible Party):
Lawson Health Research Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Head and Neck Cancer | Radiation: Radiotherapy to all dissected areas Radiation: Omit radiation to pN0 neck | Phase 2 |
The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.
The study will require a sample size of 90 patients randomized in a 2:3 between the two arms. Arm 1 (standard radiation therapy to tumor location and surrounding area) and Arm 2 (targeted radiation therapy to tumor location).
Patients will be followed for a total of 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 90 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Preservation of Swallowing in Resected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects: A Randomized Trial |
| Actual Study Start Date : | September 6, 2019 |
| Estimated Primary Completion Date : | September 2026 |
| Estimated Study Completion Date : | September 2026 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Standard Radiotherapy
Radiotherapy to all dissected areas
|
Radiation: Radiotherapy to all dissected areas
Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas |
|
Experimental: Radiotherapy to smaller treatment area
Omit radiation to pN0 neck
|
Radiation: Omit radiation to pN0 neck
post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck |
Primary Outcome Measures :
- Regional failure in the pN0 hemi-neck (s) [ Time Frame: Baseline to 5 years ]Rate of relapse in the pN0 neck in Arm 2 compared to historical controls
Secondary Outcome Measures :
- Swallowing Quality of life [ Time Frame: Baseline up to 12 months ]Assessed with the MD Anderson Dysphagia Inventory (MDADI) scale
- Swallowing Quality of life [ Time Frame: Baseline up to 12 months ]Assessed with the EORTC QLQ-C30 scale
- Swallowing Quality of life [ Time Frame: Baseline up to 12 months ]Assessed with the EORTC QLQ H&N 35 scale
- Health Status Quality of life [ Time Frame: Baseline up to 12 months ]Assessed with the EORTC EQ-5D-5L scale
- Overall survival [ Time Frame: Baseline to 5 years ]Defined as time from randomization to death from any cause
- Disease free survival [ Time Frame: Baseline to 5 years ]Defined as the measure of time after treatment during which no sign of cancer is found
- Local recurrence [ Time Frame: Baseline to 5 years ]Defined as Cancer that has recurred at or near the same place as the primary tumor, usually after a period of time during which the cancer could not be detected.
- Regional recurrence [ Time Frame: Baseline to 5 years ]Defined as recurrence that occurs in the lymph nodes and tissue located in the vicinity of your original cancer
- Locoregional recurrence [ Time Frame: Baseline to 5 years ]Defined as the recurrence of cancer cells at the same site as the original tumor and/or the regional lymph nodes after a disease free period.
- Rate of salvage treatment (surgery +/- radiotherapy) in the pN0 neck and freedom from unsalvageable neck recurrence [ Time Frame: Baseline 5 years ]Rate of salvage treatment (surgery +/- radiotherapy) in the pN0 neck and freedom from
- Rate of feeding tub insertion and rate of feeding tube use at 1-year post randomization [ Time Frame: Randomization to 1 year post randomization ]Rate of feeding tub insertion and rate of feeding tube use at 1-year post randomization
- Swallowing function [ Time Frame: Baseline to 1 year ]Measured by the Modified Barium Swallow Impairment (MBsimp) score
- Swallowing function [ Time Frame: Baseline to 1 year ]Measured by the Dynamic Imaging Grade of Swallowing Toxicity score
- Swallowing function [ Time Frame: Baseline to 1 year ]Measured by the Functional Oral Intake Score
- Rate of toxicity [ Time Frame: Baseline to 5 years ]Assessed using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4
- Rate of failure in the clinically node negative neck [ Time Frame: Baseline to 5 years ]defined as time from randomization to failure in the cN0 neck
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Willing to provide informed consent
- ECOG performance status 0-2
- Histologically confirmed, resected oral cavity squamous cell carcinoma with at least ipsilateral selective neck disection
- Patient has pathological features that are indications for PORT: positive or close (≤ 3 mm) margin, presence of LVI or PNU, pT3 or pT4 disease, positive lymph nodes, and PORT is recommended by treating physician
- Pathologically lympth node negative in at least one dissected hemi-neck with at least 10 nodes recovered in each pN0 hemi-neck
Exclusion Criteria:
- Serious medical comorbidities or other contraindications to radiotherapy
- Prior history of head and neck cancer within 5 years
- Any other active invasive malignancy, except non-melanotic skin cancers
- Prior head and neck radiation at any time
- Prior oncologic head and neck surgery in the oral cavity or neck
- Metastatic disease
- Locoregional disease recurrence identified following surgical resection but prior to the start of radiotherapy
- Inability to attend full course of radio therapy or follow-up visits
- Unable or unwilling to complete QoL questionnaires
- Pregnant or lactating women
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03997643
Locations
| United States, Florida | |
| Miami Cancer Institute | Recruiting |
| Miami, Florida, United States, 33143 | |
| Contact: Noah Kalman, MD 786-596-2000 NoahK@baptisthealth.net | |
| Canada, Ontario | |
| London Regional Cancer Program | Recruiting |
| London, Ontario, Canada, N6A 5W9 | |
| Contact: Pencilla Lang, MD 519-685-8500 Pencilla.Lang@lhsc.on.ca | |
| Contact: Laura Bailey 519-685-8618 LauraD.Bailey@lhsc.on.ca | |
| Canada, Quebec | |
| CHUM | Recruiting |
| Montréal, Quebec, Canada, H2X 0A9 | |
| Contact: Houda Bahig, MD 5148908000 houda.bahig.chum@ssss.gouv.qc.ca | |
| Ireland | |
| St. Luke's Radiation Oncology Network | Recruiting |
| Rathgar, Dublin, Ireland | |
| Contact: Sinead Brennan, MD 353 1 406 5000 sinead.brennan@slh.ie | |
| Beaumont St. Luke's Centre | Recruiting |
| Dublin, Leinster, Ireland, D09FT51 | |
| Contact: Sinead Brennan 353 1 406 5000 sinead.brennan@slh.ie | |
| Cork University Hospital | Recruiting |
| Wilton, Cork, Ireland | |
| Contact: Kathy Rock, MD 1 353 86 8420854 kathy.rock@hse.ie | |
| United Kingdom | |
| Beatson West of Scotland Cancer Centre | Recruiting |
| Glasgow, United Kingdom, G12 OYN | |
| Contact: Claire Paterson, MD 0141 301 7066 Claire.Paterson2@ggc.scot.nhs.uk | |
Sponsors and Collaborators
Lawson Health Research Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Lawson Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT03997643 |
| Other Study ID Numbers: |
PRESERVE |
| First Posted: | June 25, 2019 Key Record Dates |
| Last Update Posted: | January 25, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Lawson Health Research Institute:
|
Radiation Therapy Oral Cavity Squamous Cell Carcinoma Randomized Trial |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site |